AU2015296555B2 - Flagellin compositons and uses - Google Patents

Flagellin compositons and uses Download PDF

Info

Publication number
AU2015296555B2
AU2015296555B2 AU2015296555A AU2015296555A AU2015296555B2 AU 2015296555 B2 AU2015296555 B2 AU 2015296555B2 AU 2015296555 A AU2015296555 A AU 2015296555A AU 2015296555 A AU2015296555 A AU 2015296555A AU 2015296555 B2 AU2015296555 B2 AU 2015296555B2
Authority
AU
Australia
Prior art keywords
aac
mutant
artificial sequence
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015296555A
Other languages
English (en)
Other versions
AU2015296555A1 (en
Inventor
Vadim Mett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genome Protection Inc
Original Assignee
Genome Protection Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genome Protection Inc filed Critical Genome Protection Inc
Publication of AU2015296555A1 publication Critical patent/AU2015296555A1/en
Assigned to GENOME PROTECTION, INC. reassignment GENOME PROTECTION, INC. Request for Assignment Assignors: CLEVELAND BIOLABS, INC.
Application granted granted Critical
Publication of AU2015296555B2 publication Critical patent/AU2015296555B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015296555A 2014-07-30 2015-07-29 Flagellin compositons and uses Ceased AU2015296555B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US62/031,116 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US62/110,744 2015-02-02
US201562117366P 2015-02-17 2015-02-17
US62/117,366 2015-02-17
PCT/US2015/042684 WO2016019034A1 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses

Publications (2)

Publication Number Publication Date
AU2015296555A1 AU2015296555A1 (en) 2017-02-23
AU2015296555B2 true AU2015296555B2 (en) 2020-05-21

Family

ID=55218277

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015296555A Ceased AU2015296555B2 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses
AU2015296298A Ceased AU2015296298B2 (en) 2014-07-30 2015-07-30 Flagellin-based agents and uses including effective vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015296298A Ceased AU2015296298B2 (en) 2014-07-30 2015-07-30 Flagellin-based agents and uses including effective vaccination

Country Status (14)

Country Link
US (9) US10202426B2 (enExample)
EP (2) EP3174893B1 (enExample)
JP (3) JP6940916B2 (enExample)
KR (1) KR20170031251A (enExample)
CN (2) CN107087411B (enExample)
AU (2) AU2015296555B2 (enExample)
BR (1) BR112017001796A2 (enExample)
CA (2) CA2994218A1 (enExample)
EA (2) EA035372B1 (enExample)
ES (1) ES2816630T3 (enExample)
IL (2) IL250334B (enExample)
MX (2) MX385845B (enExample)
WO (2) WO2016019034A1 (enExample)
ZA (1) ZA201701286B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
JP6762030B2 (ja) 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
UY37816A (es) 2017-07-20 2019-02-28 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
CN112203675A (zh) * 2018-04-24 2021-01-08 基因组保护股份有限公司 用于改善虚弱和衰老的方法
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
US20220024991A1 (en) * 2018-12-07 2022-01-27 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
KR102169663B1 (ko) * 2019-03-28 2020-10-26 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
WO2021041822A1 (en) * 2019-08-30 2021-03-04 Genome Protection. Inc. Methods of increasing vaccine efficacy
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
JP7598660B2 (ja) * 2020-06-04 2024-12-12 ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
KR20240027752A (ko) * 2021-06-30 2024-03-04 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 플라겔린의 폐 전달을 위한 에어로졸 조성물
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
IL317229A (en) * 2022-06-01 2025-01-01 Flag Bio Inc RNA helpers, methods and uses thereof
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
US20240173397A1 (en) * 2022-11-29 2024-05-30 George Mason University Limiting viral infection and replication in stem cells
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain
JP1793517S (ja) * 2024-08-22 2025-04-21 船舶用推進機用リモートコントローラー

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246303A1 (en) * 2003-12-02 2009-10-01 Gudkov Andrei V Method for Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
WO1992005816A1 (de) 1990-09-28 1992-04-16 Gebrüder Sulzer Aktiengesellschaft Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
CN1447819B (zh) 2000-01-31 2011-06-22 妙甯公司 人cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
AU2004296828B2 (en) * 2003-12-02 2011-07-07 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
JP5094407B2 (ja) 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
EP1838340B1 (en) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
WO2008157473A1 (en) 2007-06-15 2008-12-24 Immurx, Inc. Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
CA2695385A1 (en) 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
KR101811965B1 (ko) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
US8486408B2 (en) * 2008-10-03 2013-07-16 Emory University Methods for the treatment of graft-versus-host disease
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
CA2777198C (en) * 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2547362B1 (en) * 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246303A1 (en) * 2003-12-02 2009-10-01 Gudkov Andrei V Method for Reducing The Effects of Chemotherapy Using Flagellin Related Polypeptides
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH K D ET AL, "Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility", NATURE IMMUNOLOGY,, (2003-12-01), vol. 4, no. 12, pages 1247 - 1253 *

Also Published As

Publication number Publication date
BR112017001796A2 (pt) 2018-02-14
EA035372B1 (ru) 2020-06-03
JP2017523184A (ja) 2017-08-17
US10202426B2 (en) 2019-02-12
ZA201701286B (en) 2018-04-25
CA2994289A1 (en) 2016-02-04
US20210269491A1 (en) 2021-09-02
EP3174893A4 (en) 2018-01-03
WO2016019134A1 (en) 2016-02-04
EA201790273A1 (ru) 2017-07-31
US10336793B2 (en) 2019-07-02
MX2017001406A (es) 2017-08-28
US20190233478A1 (en) 2019-08-01
CN107087411B (zh) 2021-06-29
EA201790294A1 (ru) 2017-08-31
US20200392190A1 (en) 2020-12-17
IL250331A0 (en) 2017-03-30
EP3174893B1 (en) 2020-05-06
CN107087411A (zh) 2017-08-22
EA037407B1 (ru) 2021-03-25
IL250334A0 (en) 2017-03-30
US20180354995A1 (en) 2018-12-13
MX2017001279A (es) 2017-08-07
KR20170031251A (ko) 2017-03-20
CA2994218A1 (en) 2016-02-04
EP3174552B1 (en) 2020-09-16
EP3174552A1 (en) 2017-06-07
AU2015296555A1 (en) 2017-02-23
JP2021191781A (ja) 2021-12-16
AU2015296298A1 (en) 2017-03-16
EP3174893A1 (en) 2017-06-07
JP6940916B2 (ja) 2021-09-29
US20200277339A1 (en) 2020-09-03
US10975127B2 (en) 2021-04-13
IL250331B (en) 2021-06-30
AU2015296298A8 (en) 2017-03-23
US20210340190A1 (en) 2021-11-04
EP3174552A4 (en) 2018-02-28
US20170266278A1 (en) 2017-09-21
WO2016019134A8 (en) 2016-03-31
US10730915B2 (en) 2020-08-04
US11542306B2 (en) 2023-01-03
AU2015296298B2 (en) 2020-05-21
US10669316B2 (en) 2020-06-02
US11034733B2 (en) 2021-06-15
JP2017523180A (ja) 2017-08-17
WO2016019034A1 (en) 2016-02-04
IL250334B (en) 2021-09-30
ES2816630T3 (es) 2021-04-05
US20180251498A1 (en) 2018-09-06
JP6646039B2 (ja) 2020-02-14
CA2994289C (en) 2023-03-14
CN107073092A (zh) 2017-08-18
MX385845B (es) 2025-03-18
US20190315810A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
US11034733B2 (en) Flagellin compositions and uses
CN113631195A (zh) 使用ror1抗体免疫缀合物的癌症治疗
TW202537643A (zh) 抗體-藥物結合物之用途
RS53327B (sr) Monoklonsko antitelo na cd44, za korišćenje u lečenju karcinoma skvamoznih ćelija glave i vrata
CN111132696A (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
US20220024991A1 (en) Engineered flagellin-derived compositions and uses
JP2022527412A (ja) がんの治療にセネカバレーウイルス（ｓｖｖ）を使用する組成物および方法
TW202207990A (zh) 含有α-烯醇酶抗體之藥物共軛物及其用途
AU2020270046B2 (en) Alkaline phosphate-based oncology treatments
WO2016014899A1 (en) Flagellin derivatives and uses
HK1237803B (en) Flagellin compositions and uses
HK1237803A1 (en) Flagellin compositions and uses
CN115282280A (zh) TGF-β1信号抑制剂的新用途
CA3167799C (en) Combined use of pertuzumab, trastuzumab, and anthracycline-based chemotherapy for neoadjuvant therapy of early-stage her2-positive breast cancer
WO2015127227A1 (en) Uses of flagellin for improved chemotherapy
US11491206B1 (en) Compositions and methods for the treatment of trail-resistant cancer
WO2016073733A1 (en) Methods of treating cancer using lipopeptides
WO2022192796A1 (en) Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration
CN119303095A (zh) 溶瘤病毒联合靶向抗体及化疗药物在抑制结肠癌肝转移中的应用
CN106699892A (zh) 肺鳞癌中dnah5融合基因及其用途
Costa et al. Etoposide e dexametasona como primeira linha em idosos com comorbidades portadores de Linfoma Difuso de Grandes Células B

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GENOME PROTECTION, INC.

Free format text: FORMER APPLICANT(S): CLEVELAND BIOLABS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired